PRESS RELEASE: Dapagliflozin as Monotherapy -2-

22nd Jun 2010 15:00

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that dapagliflozin will receive regulatory approval or, if approved, that it will become a commercially successful product. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2009 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business. For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363). CONTACT: Media: Bristol-Myers Squibb Ken Dominski, +1 609-252-5251 [email protected] or AstraZeneca Jim Minnick, +1 302-885-5135 [email protected] or Investors: Bristol-Myers Squibb John Elicker, +1 609-252-4611 [email protected] or AstraZeneca Karl Hard, +44-20-7304-5322 [email protected] or AstraZeneca Clive Morris, +44-207-304-5084 [email protected] SOURCE: Bristol-Myers Squibb Copyright Business Wire 2010 Order free Annual Report for AstraZeneca UK Ltd Visit http://djnweurope.ar.wilink.com/?ticker=GB0009895292 or call +44 (0)208 391 6028 (END) Dow Jones Newswires June 22, 2010 10:00 ET (14:00 GMT)